Genomic Surveillance of SARS-CoV-2 in the Southern Province of Zambia: Detection and Characterization of Alpha, Beta, Delta, and Omicron Variants of Concern

Viruses. 2022 Aug 24;14(9):1865. doi: 10.3390/v14091865.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) have significantly impacted the global epidemiology of the pandemic. From December 2020 to April 2022, we conducted genomic surveillance of SARS-CoV-2 in the Southern Province of Zambia, a region that shares international borders with Botswana, Namibia, and Zimbabwe and is a major tourist destination. Genetic analysis of 40 SARS-CoV-2 whole genomes revealed the circulation of Alpha (B.1.1.7), Beta (B.1.351), Delta (AY.116), and multiple Omicron subvariants with the BA.1 subvariant being predominant. Whereas Beta, Delta, and Omicron variants were associated with the second, third, and fourth pandemic waves, respectively, the Alpha variant was not associated with any wave in the country. Phylogenetic analysis showed evidence of local transmission and possible multiple introductions of SARS-CoV-2 VOCs in Zambia from different European and African countries. Across the 40 genomes analysed, a total of 292 mutations were observed, including 182 missense mutations, 66 synonymous mutations, 23 deletions, 9 insertions, 1 stop codon, and 11 mutations in the non-coding region. This study stresses the need for the continued monitoring of SARS-CoV-2 circulation in Zambia, particularly in strategically positioned regions such as the Southern Province which could be at increased risk of introduction of novel VOCs.

Keywords: COVID-19; SARS-CoV-2; Zambia; spike mutations; variants of concern; whole-genome sequencing.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / epidemiology
  • Codon, Terminator
  • Genomics
  • Humans
  • Mutation
  • Phylogeny
  • SARS-CoV-2* / genetics
  • Zambia / epidemiology

Substances

  • Codon, Terminator

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This research was supported by the Africa Centre of Excellence for Infectious Disease of Humans and Animals (ACEIDHA) project (grant number P151847) funded by the World Bank. Financial support was also provided in part by the Science and Technology Research Partnership for Sustainable Development (SATREPS) (grant number JP22jm0110019), grants for the Japan Program for Infectious Diseases Research and Infrastructure (grant number JP21wm0125008, JP20wm0225003) from Japan Agency for Medical Research and Development (AMED), and by the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme under the PANDORA-ID-NET Consortium (EDCTP Reg/Grant RIA2016E-1609). The funders had no role in study design, collection, analysis and interpretation of data, manuscript writing, and decision to submit the article for publication.